Promoter hypermethylation as an epigenetic component in Type I and Type II endometrial cancers.

Published

Journal Article (Review)

Epigenetic mechanisms that result in aberrant gene expression are a prominent feature of many cancer types. One main epigenetic mechanism for gene silencing involves promoter hypermethylation. Type I and type II endometrial cancers exhibit differing clinical, histologic, and molecular genetic characteristics. We hypothesize that these differences also extend to epigenetic phenomena. Promoter methylation analysis of 11 genes in a panel of endometrial cancers supports this hypothesis. These initial data indicate that promoter hypermethylation events occur frequently in type 1 cancer and were not detected in type II cancers using this panel of loci. These data tend to support the hypothesis that type I and type II endometrial cancers will exhibit distinct patterns of gene silencing based on promoter hypermethylation events.

Full Text

Duke Authors

Cited Authors

  • Risinger, JI; Maxwell, GL; Berchuck, A; Barrett, JC

Published Date

  • March 2003

Published In

Volume / Issue

  • 983 /

Start / End Page

  • 208 - 212

PubMed ID

  • 12724225

Pubmed Central ID

  • 12724225

Electronic International Standard Serial Number (EISSN)

  • 1749-6632

International Standard Serial Number (ISSN)

  • 0077-8923

Digital Object Identifier (DOI)

  • 10.1111/j.1749-6632.2003.tb05975.x

Language

  • eng